ChitogenXCompany Overview
Company Type: Public Company
Website: www.chitogenx.com
Number of Employees: -
Ticker: CHGX (CNSX)
Year Founded: 2015


Business Description
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of sports medicine surgeries in Canada. It develops Ortho-R, a formulation for rotator cuff repair; Ortho-M, a biopolymer for meniscus repair; Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was formerly known as Ortho Regenerative Technologies Inc. and changed its name to ChitogenX Inc. in September 2022. ChitogenX Inc. was incorporated in 2015 and is headquartered in Kirkland, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
8.3
EBITDA
(3.9)
Total Enterprise Value
11.9
TEV/EBITDA
NM
EBIT
(4.0)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(4.3)
Total Debt
3.7
Price/Tang BV
NM
Total Assets
0.7
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023


Estimates Snapshot (Current Fiscal Year End: Jan-31-2024 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.02)
(0.02)
(0.09)
(0.06)
(0.07)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00

Forward Multiples (Current FY)

Price/Earnings
NM

Non-Periodic Estimates

Recommendation
Buy (1.00)
Target Price
1.35
Potential Upside
1,250.00%


Key Professionals
Name
Title
Deschamps, Philippe 
CEO, President & Director
Mainville, Luc 
Senior VP & CFO
Dumais, Frederic 
Director of Communications & Investor Relations
Allard, Guy-Paul 
VP of Legal Affairs & Corporate Secretary
Sackier, Jonathan 
Senior Vice President of Medical Affairs
Simo, Benedek 
Controller

Key Board Members
Name
Title
Laurin, Pierre 
Independent Chairman
Deschamps, Philippe 
CEO, President & Director
Cunningham, Timothy M.
Independent Director
Farr, Jack 
Member of Clinical Advisory Board
Hoemann, Caroline 
Member of Scientific Advisory Board
Norton, Brent Henry-Barry
Director
O'Donnell, Patrick T.
Independent Director
Rodeo, Scott 
Member of Clinical Advisory Board
Saviuk, Steven 
Director
Snow, Martyn 
Member of Clinical Advisory Board
Toueg, Jacques 
Member of Clinical Advisory Board
Walthall, Howard P.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
16667 Hymus Boulevard | Kirkland, QC | H9H 4R9 | Canada
Phone: 514-261-4735   

Current and Pending Investors
Leede Jones Gable Inc., Manitex Capital Inc. (TSXV:MNX)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.10
Market Cap (mm)
8.3
Open
 0.11
Shares Out. (mm)
83.1
Previous Close
 0.10
Float %
61.0%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.11/ 0.10
Diluted EPS Excl. Extra Items
(0.08)
52 wk High/Low
 0.31/ 0.09
P/Diluted EPS Before Extra
NM
Volume (mm)
0.01
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
0.45


 
Delayed Quote** | Last Updated on Oct-10-2023 12:00 AM (GMT-5)
CNSX:CHGX - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-04-2023
-
Private Placement
Target
ChitogenX Inc. (CNSX:CHGX)


1.61
Feb-09-2023
Feb-28-2023
Private Placement
Target
ChitogenX Inc. (CNSX:CHGX)


4.48
Feb-11-2022
Apr-06-2022
Private Placement
Target
Ortho Regenerative Technologies Inc. (nka:ChitogenX Inc. (CNSX:CHGX))


2.56
Nov-12-2021
Dec-13-2021
Private Placement
Target
Ortho Regenerative Technologies Inc. (nka:ChitogenX Inc. (CNSX:CHGX))


0.82
Dec-03-2020
Dec-03-2020
Private Placement
Target
Ortho Regenerative Technologies Inc. (nka:ChitogenX Inc. (CNSX:CHGX))
Leede Jones Gable Inc.

2.33
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-28-2023
Product-Related Announcements
ChitogenX Inc. Receives Notice of Allowance for Key Patent in United States and Canada
Sep-26-2023
Product-Related Announcements
Chitogenx Concludes Enrolment for Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial
Aug-02-2023
Auditor Changes
ChitogenX Inc. Appoints Guimond Lavallée, Chartered Professional Accountants Corporation as Auditor of the Company
Jul-19-2023
Shareholder/Analyst Calls
ChitogenX Inc. - Shareholder/Analyst Call
Jul-19-2023
Annual General Meeting
ChitogenX Inc., Annual General Meeting, Jul 19, 2023


Advisors
Most Recent Auditor
Ernst & Young LLP
Private Placement Advisors
Echelon Capital Markets


Most Recent Auditor
Ernst & Young LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
ValuEngine, Inc.

Oct 02, 2023 03:37 AM
CHGX
ValuEngine Rating and Forecast Report for CHNXF
Reports
11
ValuEngine, Inc.

Sep 12, 2022 03:26 AM
CHGX
ValuEngine Rating and Forecast Report for ORTIF
Reports
11
Zacks Small-Cap Research
Vandermosten, John D.
Dec 27, 2021 05:00 AM
CHGX
Clinical Hold Lifted in Time for 3Q:22 Results
Reports
9
Zacks Small-Cap Research
Vandermosten, John D.
Oct 25, 2021 06:00 AM
CHGX
New Blood on The Board
Reports
9
Zacks Small-Cap Research
Vandermosten, John D.
Jul 07, 2021 06:00 AM
CHGX
First Quarter Update
Reports
9
Zacks Small-Cap Research
Vandermosten, John D.
Jun 04, 2021 06:00 AM
CHGX
Clinical Hold Delays 4 - 6 Weeks
Reports
9
Zacks Small-Cap Research
Vandermosten, John D.
Dec 23, 2020 05:00 AM
CHGX
Meniscus Plan In Place
Reports
7
Zacks Small-Cap Research
Vandermosten, John D.
Nov 23, 2020 05:00 AM
CHGX
Based on our DCF model and a 15% discount rate, Ortho is valued at approximately 1.80 per share.  Our model applies a 12% probability of ultimate approval and commercialization for the RESTORE...
Reports
32
Infinata, Inc.
Infinata Research
Mar 02, 2020 04:31 AM
CHGX
Ortho Regenerative Technologies Inc. - Company Report
Reports
10
Infinata, Inc.
Infinata Research
Dec 02, 2019 06:09 AM
CHGX
Ortho Regenerative Technologies Inc. - Company Report
Reports
8


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Manitex Capital Inc.

13,599,266

16.36

1.4

Sep-29-2023


Mainville M.B.A, M.B.A., Luc 

5,022,678

6.04

0.5

Sep-25-2023


Hoemann, Caroline 

3,616,389

4.35

0.4

May-13-2023


Deschamps, Philippe 

3,506,718

4.22

0.3

Jul-26-2023


Laurin B.Sc.Pharm., M.Sc., Pierre 

2,605,432

3.13

0.3

Aug-20-2023


Norton ICD.D, M.B.A., M.D., Brent Henry-Barry

1,638,993

1.97

0.2

Jun-12-2023


Allard, Guy-Paul 

1,234,250

1.48

0.1

Aug-20-2023


Sackier, Jonathan 

630,000

0.76

0.1

May-04-2023


Simcor Canada Holdings, Inc.

517,213

0.62

0.1

Jun-12-2023


Saviuk CA, Steven 

87,265

0.10

0.0

Jun-12-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Hoemann, Caroline 
3,616,389
3,616,389
Laurin B.Sc.Pharm., M.Sc., Pierre 
2,605,432
1,692,532
Norton ICD.D, M.B.A., M.D., Brent Henry-Barry
1,638,993
1,316,493
Allard, Guy-Paul 
1,234,250
1,000,000
Manitex Capital Inc.
13,599,266
866,666
Sackier, Jonathan 
630,000
630,000
Mainville M.B.A, M.B.A., Luc 
5,022,678
350,000
Deschamps, Philippe 
3,506,718
133,385

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Ortho-C (Future), Ortho-M (Future), Ortho-R (Future), ORTHO-T (Future), Ortho-V (Future)


Upcoming Events
Date/Time
Type
Dec-29-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-29-2023
Jul-31-2023
ChitogenX Inc. (CNSX:CHGX)
SEDAR
Interim Financial Statements
515 KB
Sep-29-2023
Jul-31-2023
ChitogenX Inc. (CNSX:CHGX)
SEDAR
Interim Financial Statements
1008 KB
Sep-29-2023
-
ChitogenX Inc. (CNSX:CHGX)
SEDAR
News Releases
41 KB
Sep-28-2023
-
ChitogenX Inc. (CNSX:CHGX)
SEDAR
News Releases
33 KB
Sep-26-2023
-
ChitogenX Inc. (CNSX:CHGX)
SEDAR
News Releases
43 KB
Sep-26-2023
-
ChitogenX Inc. (CNSX:CHGX)
SEDAR
News Releases
43 KB
Sep-26-2023
-
ChitogenX Inc. (CNSX:CHGX)
SEDAR
News Releases
43 KB
Aug-02-2023
-
ChitogenX Inc. (CNSX:CHGX)
SEDAR
News Releases
27 KB
Jun-30-2023
-
ChitogenX Inc. (CNSX:CHGX)
SEDAR
News Releases
38 KB
Jun-29-2023
Apr-30-2023
ChitogenX Inc. (CNSX:CHGX)
SEDAR
Interim Financial Statements
511 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Manitex Capital Inc.
Sep-29-2023
Class A Common Shares
866,666
130,629
Private Acquisition
6.81
Multiple
Mainville M.B.A, M.B.A., Luc  (Senior VP & CFO)
Sep-25-2023
Class A Common Shares
350,000
-
Other Acquisition
7.49
Multiple
Deschamps, Philippe  (CEO, President & Director)
Jul-26-2023
Class A Common Shares
133,385
18,519
Derivative Exercise and Retained Stock
3.95
Multiple
Manitex Capital Inc.
Jun-05-2023
Class A Common Shares
713,500
252,749
Private Acquisition
5.94
Multiple
Hoemann, Caroline  (Member of Scientific Advisory Board)
May-13-2023
Class A Common Shares
2,090,222
-
Other Acquisition
136.96
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Laurin, Pierre 
Independent Chairman
514-261-4735
-

Deschamps, Philippe 
CEO, President & Director
(614) 596-2597
-
deschamps@orthorti.com
Cunningham, Timothy M.
Independent Director
514-261-4735
(781) 401-1257
TCunningham@organo.com
Farr, Jack 
Member of Clinical Advisory Board
514-261-4735
-

Hoemann, Caroline 
Member of Scientific Advisory Board
514-261-4735
-

Norton, Brent Henry-Barry
Director
514-261-4735
-
norton@orthorti.com
O'Donnell, Patrick T.
Independent Director
514-261-4735
-

Rodeo, Scott 
Member of Clinical Advisory Board
514-261-4735
-

Saviuk, Steven 
Director
514 693-8830
-
steve@manitexcapital.com
Snow, Martyn 
Member of Clinical Advisory Board
514-261-4735
-

Toueg, Jacques 
Member of Clinical Advisory Board
514-261-4735
-

Walthall, Howard P.
Independent Director
514-261-4735
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Deschamps, Philippe 
CEO, President & Director
(614) 596-2597
-
deschamps@orthorti.com
Mainville, Luc 
Senior VP & CFO
(514) 693-8854
-
mainville@orthorti.com
Dumais, Frederic 
Director of Communications & Investor Relations
(514) 782- 8803
-
dumais@valeopharma.com
Allard, Guy-Paul 
VP of Legal Affairs & Corporate Secretary
(514) 693-8832
-
allard@orthorti.com
Sackier, Jonathan 
Senior Vice President of Medical Affairs
514-261-4735
-

Simo, Benedek 
Controller
514-261-4735
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
